Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 116
Filtrar
1.
Anticancer Res ; 40(7): 3793-3799, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32620618

RESUMEN

BACKGROUND/AIM: Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of cancer worldwide. Our study focused on the axon guidance receptor roundabout guidance receptor 1 (ROBO1) as a target for monoclonal antibody therapy of HNSCC. We previously showed that saporin-conjugated anti-ROBO1 (B5209B) immunotoxin (IT-ROBO1) enhanced cytotoxic effects on HNSCC cells in combination with the photosensitizer aluminum phthalocyanine disulphonate (AlPcS2a) and illumination. We examined the effects of this combination therapy in a mouse xenograft model. MATERIALS AND METHODS: IT-ROBO1 was intraperitoneally administered to HSQ-89 (derived from Japanese maxillary sinus squamous carcinoma, RCB0789; RIKEN, Tsukuba, Japan) xenografted mice. After 3 days, AlPcS2a was injected subcutaneously around the tumor and the area was illuminated at 650 nm for 30 min. The growth of the tumor was evaluated and the effects on the tumor were examined. RESULTS: Pronounced anti-tumor effects were elicited by the administration of IT-ROBO1 and AlPcS2a with light illumination on tumor size and pathological characteristics. CONCLUSION: The results showed that photosensitizer treatment with illumination robustly enhanced the antitumor effect of the IT-ROBO1 immunotoxin.


Asunto(s)
Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Inmunotoxinas/metabolismo , Seno Maxilar/efectos de los fármacos , Proteínas del Tejido Nervioso/metabolismo , Fármacos Fotosensibilizantes/farmacología , Receptores Inmunológicos/metabolismo , Carcinoma de Células Escamosas de Cabeza y Cuello/tratamiento farmacológico , Animales , Anticuerpos Monoclonales/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Humanos , Masculino , Seno Maxilar/metabolismo , Ratones , Ratones Endogámicos BALB C , Carcinoma de Células Escamosas de Cabeza y Cuello/metabolismo , Ensayos Antitumor por Modelo de Xenoinjerto , Proteínas Roundabout
2.
J Mater Sci Mater Med ; 30(9): 97, 2019 Aug 22.
Artículo en Inglés | MEDLINE | ID: mdl-31440845

RESUMEN

Sinus elevation is a common procedure to increase bone volume in the atrophic maxilla to allow placement of dental implants. Autogenous bone is the gold standard but is limited in quantity and causes morbidity at the donor site. ß-TCP is a synthetic biomaterial commonly used in that purpose. It appears to induce a poor inflammatory response. This study aimed to evaluate the degree of edema of the sinus mucosa after sinus lift surgery according to the type of biomaterial. Forty sinuses (20 patients) were included retrospectively and divided into 2 groups according to the biomaterial that was used: synthetic biomaterial (BTCP group), natural bone (BONE group). A control group (CTRL group) was constituted by the non-grafted maxillary sinuses. Twelve measurements per sinus were realized on pre- and post-operative computed tomography and averaged to provide the sinus membrane thickness value (SM.Th). SM.Th was thicker post-operatively in the BTCP and BONE groups in comparison with the CTRL group and in comparison with pre-operative measurements. No difference was found post operatively between the BTCP and BONE groups. We found that a synthetic biomaterial (ß-TCP) induced the same degree of edema, and thus of inflammation, as natural bone. It constitutes therefore an interesting alternative to autogenous bone for maxillary sinus lifts.


Asunto(s)
Sustitutos de Huesos/efectos adversos , Trasplante Óseo/efectos adversos , Fosfatos de Calcio/efectos adversos , Fosfatos de Calcio/química , Sinusitis Maxilar/etiología , Elevación del Piso del Seno Maxilar/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Materiales Biocompatibles/efectos adversos , Sustitutos de Huesos/química , Trasplante Óseo/métodos , Implantación Dental Endoósea/efectos adversos , Implantación Dental Endoósea/métodos , Implantes Dentales/efectos adversos , Femenino , Humanos , Inflamación/etiología , Inflamación/patología , Masculino , Seno Maxilar/efectos de los fármacos , Seno Maxilar/patología , Sinusitis Maxilar/patología , Persona de Mediana Edad , Estudios Retrospectivos , Elevación del Piso del Seno Maxilar/métodos
3.
Biomed Res Int ; 2019: 7267062, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31008111

RESUMEN

PURPOSE: To date, it remains unknown whether the addition of platelet-rich fibrin (PRF) to bone grafts actually improves the effectiveness of maxillary sinus augmentation. This study aimed to perform a meta-analysis to evaluate the efficacy of PRF in sinus lift. MATERIALS AND METHODS: PubMed, Embase, and the Cochrane Library were searched. Randomized controlled studies were identified. The risk of bias was evaluated using the Cochrane Collaboration tool. RESULTS: Five RCTs were included in our meta-analysis. Clinical, radiographic, and histomorphometric outcomes were considered. No implant failure or graft failure was detected in all included studies within the follow-up period. The percentage of contact length between newly formed bone substitute and bone in the PRF group was lower but lacked statistical significance (3.90%, 95% CI, -2.91% to 10.71%). The percentages of new bone formation (-1.59%, 95% CI, -5.36% to 2.18%) and soft-tissue area (-3.73%, 95% CI, -10.11% to 2.66%) were higher in the PRF group but were not significantly different. The percentage of residual bone graft was not significant in either group (4.57%, 95% CI, 0% to 9.14%). CONCLUSIONS: Within the limitations of this review, it was concluded that there were no statistical differences in survival rate, new bone formation, contact between newly formed bone and bone substitute, percentage of residual bone graft (BSV/TV), and soft-tissue area between the non-PRF and PRF groups. Current evidence supporting the necessity of adding PRF to bone graft in sinus augmentation is limited.


Asunto(s)
Trasplante Óseo/métodos , Implantación Dental Endoósea/métodos , Fibrina Rica en Plaquetas , Elevación del Piso del Seno Maxilar , Regeneración Ósea/efectos de los fármacos , Sustitutos de Huesos/farmacología , Humanos , Seno Maxilar/efectos de los fármacos , Seno Maxilar/patología , Ensayos Clínicos Controlados Aleatorios como Asunto
4.
Mater Sci Eng C Mater Biol Appl ; 97: 103-115, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30678894

RESUMEN

Injectable bone cement (IBC) such as those based on methacrylates and hydraulic calcium phosphate and calcium sulfate-based cements have been used extensively for filling bone defects with acceptable clinical outcomes. There is a need however for novel IBC materials that can address some of the inherent limitations of currently available formulations to widen the clinical application of IBC. In this study, we characterized a novel hydraulic IBC formulation consisting of bioactive strontium-doped hardystonite (Sr-HT) ceramic microparticles and sodium dihydrogen phosphate, herein named Sr-HT phosphate cement (SPC). The resultant cement is comprised of two distinct amorphous phases with embedded partially reacted crystalline reactants. The novel SPC formulation possesses a unique combination of physicochemical properties suitable for use as an IBC, and demonstrates in vitro cytocompatibility when seeded with primary human osteoblasts. In vivo injection of SPC into rabbit sinus defects show minor new bone formation at the SPC periphery, similar to those exhibited in sinus defects filled with a clinically available calcium phosphate cement. The current SPC formulation presented in this paper shows promise as a clinically applicable IBC which can be further enhanced with additives.


Asunto(s)
Cementos para Huesos/química , Cementos para Huesos/farmacología , Ensayo de Materiales/métodos , Silicatos/química , Estroncio/química , Animales , Hueso Esponjoso , Proliferación Celular , Células Cultivadas , Concentración de Iones de Hidrógeno , Inyecciones , Seno Maxilar/efectos de los fármacos , Seno Maxilar/fisiología , Seno Maxilar/cirugía , Osteoblastos/efectos de los fármacos , Osteogénesis , Fosfatos/química , Conejos , Difracción de Rayos X
5.
Oral Maxillofac Surg ; 22(4): 443-450, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30345483

RESUMEN

PURPOSE: Augmentation of the maxillary sinus floor with bone grafting is commonly used for successful treatment of edentulous posterior maxilla with dental implants, and it is essential to maintain good bone volume and quality for long-term success of dental implants. The aim of this experimental study was to investigate the local and systemic effects of boric acid on new bone formation after maxillary sinus floor augmentation (MSFA). MATERIALS AND METHODS: Twenty-four male, New Zealand rabbits were randomly divided into three groups with eight rabbits each, and bilateral MSFA was performed in each animal. An autogenous bone/xenograft mixture was used to augment the maxillary sinuses in each group. Group 1 was determined as control with no additional materials, whereas 3 mg/kg boric acid (BA) was added to the mixture in group 2, and 3 mg/kg boric acid solution added to drinking water daily in group 3. RESULTS: The animals were sacrificed and also histologic, histomorphometric, and immunnohistochemical analyses were performed at weeks 4 and 8. At week 4, bone regeneration was better in the local BA group than in the control and systemic BA groups (p < 0.05). However, no significant difference was found among the groups in terms of bone regeneration at the end of week 8 (p > 0.05). CONCLUSION: Significant higher new bone formation was revealed by BA at early healing especially with local application. BA may be a therapeutic option for improving the bone regeneration.


Asunto(s)
Ácidos Bóricos/uso terapéutico , Osteogénesis/efectos de los fármacos , Elevación del Piso del Seno Maxilar/métodos , Administración Oral , Animales , Sustitutos de Huesos/administración & dosificación , Sustitutos de Huesos/uso terapéutico , Trasplante Óseo/métodos , Ácidos Bóricos/administración & dosificación , Masculino , Seno Maxilar/anatomía & histología , Seno Maxilar/efectos de los fármacos , Seno Maxilar/cirugía , Conejos
6.
Int Forum Allergy Rhinol ; 8(4): 482-489, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29334430

RESUMEN

BACKGROUND: The ciprofloxacin-coated sinus stent (CSS) has unique therapeutic potential to deliver antibiotics to the sinuses. The objective of this study is to evaluate the efficacy of the CSS stent in eliminating Pseudomonas aeruginosa infection in a rabbit model of sinusitis. METHODS: A ciprofloxacin-eluting sinus stent was created by coating ciprofloxacin/Eudragit RS100 on biodegradable poly-D/L-lactic acid (2 mg). After analyzing in-vitro inhibition of P aeruginosa (PAO-1 strain) biofilm formation, a total of 8 stents (4 shams, 4 CSSs) were placed unilaterally in rabbit maxillary sinuses via dorsal sinusotomy after inducing infection for 1 week with PAO-1. Animals were assessed 2 weeks after stent insertion with nasal endoscopy, sinus culture, computed tomography (CT) scan, histopathology, and scanning electron microscopy (SEM). RESULTS: PAO-1 biofilm formation was significantly reduced in vitro with exposure to the CSS (p < 0.0001). Insertion of the stent in PAO-1-infected rabbits for 2 weeks resulted in significant improvement in sinusitis according to endoscopy scoring (p < 0.0001) and CT scoring (p < 0.002). Histology and SEM revealed marked improvement in the structure of the mucosa and submucosa with no detection of biofilm structures in the CSS cohort. CONCLUSION: Although this study had a small sample size, we identified robust therapeutic efficacy of the CSS by reducing bacterial load and biofilm formation of P aeruginosa in a preclinical model of sinusitis after placement for 2 weeks.


Asunto(s)
Antibacterianos/uso terapéutico , Biopelículas/efectos de los fármacos , Ciprofloxacina/uso terapéutico , Seno Maxilar/efectos de los fármacos , Mucosa Nasal/patología , Infecciones por Pseudomonas/terapia , Pseudomonas aeruginosa/fisiología , Sinusitis/terapia , Animales , Carga Bacteriana , Biopelículas/crecimiento & desarrollo , Células Cultivadas , Modelos Animales de Enfermedad , Stents Liberadores de Fármacos , Endoscopía , Humanos , Seno Maxilar/cirugía , Conejos
7.
Int J Nanomedicine ; 12: 2933-2939, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28435269

RESUMEN

BACKGROUND: Staphylococcus aureus biofilms contribute significantly to the recalcitrant nature of chronic rhinosinusitis. In previous studies, it has been shown that silk fibroin-nano silver solution can eliminate S. aureus biofilms in vitro, which suggests a potential role of this novel agent in the treatment of biofilm-associated diseases, such as sinusitis. OBJECTIVE: The aim of this study was to investigate the efficacy of silk fibroin-nano silver solution as a topical anti-biofilm agent in a rabbit model of sinusitis. METHODS: Biofilm-associated sinusitis models were established in 24 New Zealand White rabbits by gelatin sponge placement and S. aureus inoculation through a hole drilled into the anterolateral wall of the right maxillary sinus. After 4 weeks, indwelling catheters were placed into the maxillary sinus. Different concentrations of silk fibroin-nano silver solution or normal saline were irrigated slowly into the maxillary sinus via the indwelling catheters. After 7 days of irrigation, the rabbits were sacrificed. The sinus mucosa was harvested and examined for biofilm biomass as well as morphological integrity of the epithelium by scanning electron microscopy. RESULTS: Silk fibroin-nano silver solution was found to be most effective in reducing the biomass of the S. aureus biofilms at a concentration of 384 mg/L, followed by the concentration of 153.6 mg/L, when compared with saline. After treatment with 384 mg/L silk fibroin-nano silver solution, the biofilms were completely eliminated and the injured epithelium was almost restored with regenerated cilia on the surface. CONCLUSION: Silk fibroin-nano silver solution was found to be an effective topical agent against S. aureus biofilms in the rabbit model of sinusitis, and its effect was concentration-dependent.


Asunto(s)
Antibacterianos/farmacología , Plata/farmacología , Sinusitis/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Administración Tópica , Animales , Antibacterianos/administración & dosificación , Antibacterianos/química , Biopelículas/efectos de los fármacos , Catéteres de Permanencia , Enfermedad Crónica , Fibroínas/química , Seno Maxilar/efectos de los fármacos , Seno Maxilar/microbiología , Seno Maxilar/patología , Microscopía Electrónica de Rastreo , Nanocompuestos/química , Conejos , Plata/administración & dosificación , Plata/química , Sinusitis/microbiología , Infecciones Estafilocócicas/microbiología , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/patogenicidad , Staphylococcus aureus/fisiología
8.
Implant Dent ; 26(2): 178-186, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-28301382

RESUMEN

OBJECTIVE: Although increasing evidence has shown that long noncoding RNAs (lncRNAs) play an important regulatory role in pluripotency and differentiation of mesenchymal stem cells, little is known about the role of lncRNA in maxillary sinus membrane stem cells (MSMSCs). The goal of this study was to investigate the expression profile and function of lncRNAs on osteogenic differentiation of MSMSCs. MATERIALS AND METHODS: By using lncRNA microarray, we identify a novel osteogenesis differentiation-related lncRNA of MSMSCs (lncRNA-MODR). The functional role of lncRNA-MODR in regulating osteogenesis was evaluated by quantitative real-time polymerase chain reaction, western blot, and alizarin red staining. Bioinformatic analyses of the predicted target genes (gene ontology, pathway, and network analysis) were applied for further study of lncRNA-MODR. RESULTS: We show that lncRNA-MODR is gradually upregulated during osteogenic differentiation. lncRNA-MODR overexpression upregulated, whereas lncRNA-MODR silencing decreased the expression of the osteogenic key marker, runt-related transcription factor 2 (RUNX2). In-depth analyses showed that lncRNA-MODR acts as a molecular sponge for microRNA-454 (miR-454) and that prevents RUNX2 from mi-454-mediated suppression. CONCLUSION: The lncRNAs act as a competing endogenous RNA to sequester microRNA-454 (miR-454), leading to heightened RUNX2 expression and thus promotes osteogenesis of MSMSCs.


Asunto(s)
Seno Maxilar/efectos de los fármacos , MicroARNs/metabolismo , Osteogénesis/fisiología , ARN Largo no Codificante/metabolismo , Células Madre/efectos de los fármacos , Western Blotting , Diferenciación Celular/efectos de los fármacos , Subunidad alfa 1 del Factor de Unión al Sitio Principal/metabolismo , Humanos , Seno Maxilar/citología , Análisis de Secuencia por Matrices de Oligonucleótidos , Reacción en Cadena en Tiempo Real de la Polimerasa , Células Madre/fisiología
9.
Cell Physiol Biochem ; 40(5): 944-952, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27941347

RESUMEN

BACKGROUND: Osteotome sinus floor elevation is a less invasive approach to augment an insufficient alveolar bone at the posterior maxilla for dental implantation. However, this approach has some limitations due to the lack of sinus lift tools available for clinical use and the small transcrestal access to the maxillary sinus floor. We recently invented shape-memory Ni/Ti alloy wire containing tube elevators for transcrestal detaching maxillary sinus mucosa, and developed goat ex vivo models for direct visualizing the effectiveness of detaching sinus mucosa in real time during transcrestal maxillary sinus floor elevation. METHODS: We evaluated our invented elevators, namely elevator 012 and elevator 014, for their effectiveness for transcrestal detaching maxillary sinus mucosa using the goat ex vivo models. We measured the length of sinus mucosa detached in mesial and distal directions or buccal and palatal directions, and the space volume created by detaching maxillary sinus mucosa in mesial, distal, buccal and palatal directions using the invented elevators. RESULTS: Elevator 012 had a shape-memory Ni/Ti alloy wire with a diameter of 0.012 inch, while elevator 014 had its shape-memory Ni/Ti alloy wire with a diameter of 0.014 inch. Elevator 012 could detach the goat maxillary sinus mucosa in the mesial or distal direction for 12.1±4.3 mm, while in the buccal or palatal direction for 12.5±6.7 mm. The elevator 014 could detach the goat maxillary sinus mucosa for 23.0±4.9 mm in the mesial or distal direction, and for 19.0±8.1 mm in the buccal or palatal direction. An average space volume of 1.7936±0.2079 ml was created after detaching the goat maxillay sinus mucosa in both mesial/distal direction and buccal/palatal direction using elevator 012; while the average space volume created using elevator 014 was 1.8764±0.2366 ml. CONCLUSION: Both two newly invented tube elevators could effectively detach the maxillary sinus mucosa on the goat ex vivo sinus models. Moreover, elevator 014 has advantages over the elevator 012 for the capability to detach sinus mucosa.


Asunto(s)
Seno Maxilar/efectos de los fármacos , Membrana Mucosa/efectos de los fármacos , Níquel/farmacología , Elevación del Piso del Seno Maxilar/métodos , Titanio/farmacología , Animales , Estudios de Factibilidad , Femenino , Cabras , Masculino
10.
Curr Med Chem ; 23(24): 2736-2745, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27356533

RESUMEN

Exhaled nitric oxide (NO) originates from the upper airways, and takes action, to varying extents, in regulation, protection and defense, as well as in noxious processes. Nitric oxide retains important functions in a wide range of physiological and pathophysiological processes of the human body, including vaso-regulation, antimicrobial activity, neurotransmission and respiration. This review article reports the ongoing investigations regarding the source, biology and relevance of NO within upper respiratory tract. In addition, we discuss the role of NO, originating from nasal and paranasal sinuses, in inflammatory disorders such as allergic rhinitis, sinusitis, primary ciliary dyskinesia, and cystic fibrosis.


Asunto(s)
Óxido Nítrico/metabolismo , Sistema Respiratorio/metabolismo , Asma/diagnóstico , Asma/metabolismo , Humanos , Síndrome de Kartagener/diagnóstico , Síndrome de Kartagener/metabolismo , Seno Maxilar/efectos de los fármacos , Seno Maxilar/metabolismo , Óxido Nítrico/análisis , Donantes de Óxido Nítrico/farmacología , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II/metabolismo , Sistema Respiratorio/efectos de los fármacos , Sinusitis/diagnóstico , Sinusitis/metabolismo
11.
In Vitro Cell Dev Biol Anim ; 52(7): 757-71, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27251156

RESUMEN

Bone marrow-derived mesenchymal stem cells (BM-MSCs) have been recognized as a new strategy for maxillary sinus floor elevation. However, little is known concerning the effect of the biomechanical pressure (i.e., sinus pressure, masticatory pressure, and respiration) on the differentiation of BM-MSCs and the formation of new bone during maxillary sinus floor elevation. The differentiation of BM-MSCs into osteoblasts was examined in vitro under cyclic compressive pressure using the Flexcell® pressure system, and by immunohistochemical analysis, qRT-PCR, and Western blot. Micro-CT was used to detect bone formation and allow image reconstruction of the entire maxillary sinus floor elevation area. Differentiation of BM-MSCs into osteoblasts was significantly increased under cyclic compressive pressure. The formation of new bone was enhanced after implantation of the pressured complex of BM-MSCs and Bio-Oss during maxillary sinus floor elevation. The pressured complex of BM-MSCs and Bio-Oss promoted new bone formation and maturation in the rabbit maxillary sinus. Stem cell therapy combined with this tissue engineering technique could be effectively used in maxillary sinus elevation and bone regeneration.


Asunto(s)
Seno Maxilar/crecimiento & desarrollo , Trasplante de Células Madre Mesenquimatosas , Osteoblastos/citología , Osteogénesis , Animales , Células de la Médula Ósea/citología , Diferenciación Celular/genética , Humanos , Seno Maxilar/efectos de los fármacos , Células Madre Mesenquimatosas , Minerales/administración & dosificación , Osteoblastos/efectos de los fármacos , Conejos , Elevación del Piso del Seno Maxilar/métodos
12.
J Clin Periodontol ; 42(1): 81-8, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25370371

RESUMEN

AIM: The objective of study was to determine the osteogenic potential of bone morphogenetic protein-2 (BMP-2) loaded onto a particulate porcine bone mineral (PBM) biomaterial using a sinus augmentation model. METHODS: Release kinetics of BMP-2/PBM was determined in vitro. Eight rabbits received BMP-2/PBM or PBM alone into contra-lateral sinus sites. The animals were killed following a 2-week healing interval for micro-CT and histometrical analysis. RESULTS: Approximately 40% of the BMP-2 was released from PBM over the first 3 days in vitro; release maintained at a reduced level through day 21. In vivo, total augmented implant volume did not differ significantly between treatments. However, local bone formation was enhanced in the BMP-2/PBM group compared with PBM control (10.5% versus 6.6%; p = 0.03), specifically in the central aspect of the PBM implant (14.2% versus 5.5%; p < 0.01) and adjoining the Schneiderian membrane (11.9% versus 5.0%; p < 0.05). There were no significant overall differences in residual biomaterial and fibrovascular tissue. CONCLUSION: Bone morphogenetic protein-2 enhanced local bone formation in the rabbit maxillary sinus model following implantation using a PBM carrier.


Asunto(s)
Materiales Biocompatibles/uso terapéutico , Proteína Morfogenética Ósea 2/uso terapéutico , Sustitutos de Huesos/uso terapéutico , Osteogénesis/efectos de los fármacos , Elevación del Piso del Seno Maxilar/métodos , Animales , Proteína Morfogenética Ósea 2/farmacocinética , Evaluación Preclínica de Medicamentos , Células Gigantes/patología , Procesamiento de Imagen Asistido por Computador/métodos , Imagenología Tridimensional/métodos , Masculino , Seno Maxilar/efectos de los fármacos , Seno Maxilar/patología , Mucosa Nasal/efectos de los fármacos , Mucosa Nasal/patología , Conejos , Distribución Aleatoria , Porcinos , Microtomografía por Rayos X/métodos
13.
Artículo en Chino | MEDLINE | ID: mdl-25522571

RESUMEN

OBJECTIVE: The aim of this study was to determine the expression of GATA-3 and the level of Th1 and Th2 cytokines upon repeated exposure to staphylococcal enterotoxin B(SEB) of different concentrations in the maxillary sinus mucosa of rabbits. METHOD: The rabbits were randomly divided into 2 groups (24 rabbits per group): low-dose SEB group and high-dose SEB group. The low-dose SEB group and high-dose SEB group received daily injections of 0.6 ng of SEB (2 ml) and 60 ng of SEB (2 ml) into the left maxillary sinus of rabbits for 28 days, respectively. Concurrent treatment of the right maxillary sinus with normal saline was used as a control. Six rabbits chosen randomly in two groups were killed on days 3, 7, 14, and 28, and to obtain the sinus mucosa from the two-side maxillary sinuses for measurement. Mucosal levels of IL-2, IL-4, IL-5, and IFN-γ were measured using ABC-ELISA. Tissue expression of GATA-3 were examined using Real-time PCR and immunohistochemistry. RESULT: IFN-γ and IL-2 levels were significantly elevated in the high-dose SEB group compared with the low-dose SEB and control groups on days 7, 14, and 28 (P < 0.05). However, IL-4 and IL-5 levels were markedly enhanced in the low-dose SEB group compared with the high-dose SEB and control groups on days 14 and 28 (P < 0.05). Real-time PCR showed that the expression of GATA-3 mRNA in the low-dose SEB group was markedly enhanced, and immunohistochemical staining illustrated that the number of GATA-3 positive cells was markedly increased in the low-dose SEB group as compared with the high-dose SEB group (P < 0.05). No significant differences were observed in GATA-3 expression between the high-dose SEB and the control groups (P > 0.05). CONCLUSION: SEB promoted Th1 cytokines production at high concentrations, and enhanced Th2 cytokines expression and Th2 immune response at low concentrations.


Asunto(s)
Citocinas/metabolismo , Enterotoxinas/farmacología , Seno Maxilar/efectos de los fármacos , Mucosa Nasal/metabolismo , Animales , Enterotoxinas/administración & dosificación , Ensayo de Inmunoadsorción Enzimática , Interferón gamma/metabolismo , Interleucina-2/metabolismo , Interleucina-4/metabolismo , Interleucina-5/metabolismo , Masculino , Seno Maxilar/metabolismo , ARN Mensajero/metabolismo , Conejos , Células TH1 , Células Th2 , Factores de Transcripción/metabolismo
15.
J Craniomaxillofac Surg ; 42(6): 990-4, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24503388

RESUMEN

Recently, several authors have shown that simultaneous sinus lift and implantation using autologous platelet-rich fibrin as the sole filling material is a reliable procedure promoting bone augmentation in the maxillary sinus. The aim of this study was to examine the effect of simultaneous sinus lift and implantation using platelet-rich fibrin as the sole grafting material on bone formation in a canine sinus model. An implant was placed after sinus membrane elevation in the maxillary sinus of six adult female mongrel dogs. The resulting space between the membrane and sinus floor was filled with autologous platelet-rich fibrin retrieved from each dog. The implants were left in place for six months. Bone tissue was seen at the lower part of the implants introduced into the sinus cavity. The height of the newly formed bone around the implants ranged from 0 mm to 4.9 mm (mean; 2.6 ± 2.0 mm) on the buccal side and from 0 mm to 4.2 mm (mean; 1.3 ± 1.8 mm) on the palatal side. The findings from this study suggest that simultaneous sinus lift and implantation using platelet-rich fibrin as sole grafting material is not a predictable and reproducible procedure, especially with respect to the bone formation around the implants in the sinus cavity.


Asunto(s)
Plaquetas/fisiología , Implantación Dental Endoósea/métodos , Fibrina/uso terapéutico , Elevación del Piso del Seno Maxilar/métodos , Animales , Perros , Femenino , Geles , Maxilar/efectos de los fármacos , Seno Maxilar/efectos de los fármacos , Modelos Animales , Osteogénesis/efectos de los fármacos , Plasma Rico en Plaquetas/fisiología , Distribución Aleatoria , Colgajos Quirúrgicos/cirugía , Factores de Tiempo , Cicatrización de Heridas/fisiología
16.
Artículo en Chino | MEDLINE | ID: mdl-25623868

RESUMEN

OBJECTIVE: To investigate the ultrastructure of ciliated epithelia and inflammatory changes upon repeated exposure to staphylococcal enterotoxin A (SEA) of different concentrations in the maxillary sinus mucosa of rabbits. METHODS: The rabbits were randomly divided into 2 groups (24 rabbits per group): low-dose SEA group and high-dose SEA group. The low-dose SEA group and high-dose SEA group received daily injections of 0.6 ng of SEA (2 ml) and 60 ng of SEA (2 ml) into the left maxillary sinus of rabbits for 28 days, respectively. Concurrent treatment of the right maxillary sinus with normal saline was used as control. Six rabbits chosen randomly in two groups were examined by computed tomography (CT) scans and then sacrificed to obtain the sinus mucosa from the two-side of maxillary sinuses for histological assessment on days 3, 7, 14 and 28. To characterize the inflammatory changes of the sinus mucosa examined using light microscope, hematoxylin and eosin (HE) and toluidine blue staining was performed. Scanning and transmission electron microscopy were performed to observe ultrastructure of ciliated epithelia in the maxillary sinus mucosa. SPSS 13.0 software was used to analyze the data. RESULTS: On days 14 and 28, CT images showed opacification of the left maxillary sinus in the high-dose SEA group. The percentage of epithelial disruption was (22.73 ± 5.72) % and (30.79 ± 4.30)% in the high-dose SEA group respectively, and were significantly greater than those in the low-dose SEA group (5.12% ± 1.98% and 5.38% ± 1.64%, q value was 10.079 and 19.132) and control group (4.08% ± 1.29% and 4.81% ± 1.62%, q value was 11.016 and 19.592, respectively, all P < 0.01). The subepithelial thickness in the high-dose SEA group was (113.34 ± 14.81)µm and (120.86 ± 12.35) µm respectively, and were significantly different from those of the low-dose SEA group [(71.08 ± 10.39)µm and (81.63 ± 9.32)µm, q value was 8.090 and 8.782] and control group [(37.45 ± 7.67)µm and (38.79 ± 7.68)µm, q value was 15.759 and 19.541, all P < 0.01]. Viewed under the electron microscope, loss of cilia was observed, a few compound cilia and cytoplasmic protrusion were found, an obvious stretching of the endoplasmic reticulum and an obvious turgescence of the mitochondria was also observed. However, in the low-dose SEA group on days 14 and 28, CT scan of the left maxillary sinus showed transparency; light microscopy observations of the maxillary sinus mucosa showed the number of eosinophils was markedly increased as compared with the high-dose SEA and control groups, the differences were significant (q value was 5.871 and 6.766 on day 14, and q value was 7.572 and 8.970 on day 28, respectively, all P < 0.05). But no significant differences were observed in epithelial disruption between the low-dose SEA and the control groups on days 14 and 28 (q value was 1.512 and 0.859 respectively, all P > 0.05); inordinate array and adhesion of cilia was observed, but cilia loss, compound cilia, cytoplasmic protrusions, mitochondrial swelling and endoplasmic reticulum stretching were not found. CONCLUSIONS: SEA may induce allergic inflammation of the sinus mucosa without damaging the structure of ciliated epithelia at low concentration. Whereas SEA impairs the structure of mitochondria and endoplasmic reticulum in ciliated epithelial cells at high concentration, and results in cilia loss and epithelial disruption, which may be one of the main reasons to induce acute sinusitis.


Asunto(s)
Cilios/ultraestructura , Enterotoxinas/toxicidad , Células Epiteliales/ultraestructura , Seno Maxilar/ultraestructura , Animales , Cilios/efectos de los fármacos , Cilios/fisiología , Costo de Enfermedad , Eosinófilos , Células Epiteliales/efectos de los fármacos , Células Epiteliales/fisiología , Recuento de Leucocitos , Seno Maxilar/efectos de los fármacos , Seno Maxilar/metabolismo , Membrana Mucosa/efectos de los fármacos , Membrana Mucosa/fisiología , Membrana Mucosa/ultraestructura , Conejos , Sinusitis
17.
Head Neck ; 35(10): E321-4, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23047661

RESUMEN

BACKGROUND: Immunoglobulin G4 (IgG4)-related sclerosing disease is a systemic disease characterized by extensive IgG4-positive plasma cells and T-lymphocyte infiltration of various organs. We present a case of a 69-year-old man with maxillary sinus IgG4 sclerosing disease, with orbital invasion treated with rituximab and dexamethasone pulse therapy. Surgery was used as well to debulk the disease and to obtain tissue for diagnosis. METHODS: A PubMed search using the key phrase "IgG4-related Sclerosing Disease" was performed. There were 304 different articles regarding the disease for a multitude of different organ sites. Of the 304 articles, there were 3 articles that reported this disease in the paranasal sinuses. CONCLUSIONS: IgG4-related sclerosing disease is a rare entity in the head and neck. There are documented reports of steroid therapy for this disease, but the patient presented here demonstrated clinical progression of disease with steroids alone. The use of combination therapy of surgery, dexamethasone, and rituximab provided clinical improvement and stable disease determined by radiographic means.


Asunto(s)
Inmunoglobulina G/inmunología , Seno Maxilar/patología , Enfermedades Orbitales/patología , Enfermedades Orbitales/cirugía , Enfermedades de los Senos Paranasales/patología , Enfermedades de los Senos Paranasales/terapia , Anciano , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Biopsia con Aguja , Enfermedad Crónica , Terapia Combinada , Descompresión Quirúrgica/métodos , Dexametasona/administración & dosificación , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Imagen por Resonancia Magnética/métodos , Masculino , Seno Maxilar/efectos de los fármacos , Seno Maxilar/cirugía , Enfermedades Orbitales/inmunología , Enfermedades de los Senos Paranasales/inmunología , Rituximab , Esclerosis , Índice de Severidad de la Enfermedad , Sinusitis/diagnóstico , Sinusitis/etiología , Tomografía Computarizada por Rayos X/métodos , Resultado del Tratamiento
18.
Br J Oral Maxillofac Surg ; 51(3): 247-52, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22766268

RESUMEN

The aim of this study was to evaluate the quantity and quality of bony regeneration after we had used recombinant human bone morphogenetic protein-7 (rhBMP-7 to augment the floor of the maxillary sinus. Nine consecutive patients with bilateral posterior maxillary atrophy who required augmentation of the sinus for interposition of implants were treated simultaneously with rhBMP-7 (Osigraft) with deproteinised bone substitute (0.5 g on the test side) and with deproteinised bone alone (2.0 g on the control side). Computed tomographic images preoperatively, immediately postoperatively, and at 4 months postoperatively showed a mean (SD) postoperative gain of 10.8 (3.0) mm on the test side and of 10.2 (1.8) mm on the control side. Histological and histomorphometric analyses of biopsy specimens showed that there was significantly more new bone on the control side (19.9 (6.8)%) than on the test side (6.6 (4.8)%). In this pilot controlled trial of the use of rhBMP-7, histological analyses showed that it resulted in the formation of less bone than treatment with inorganic bovine hydroxyapatite.


Asunto(s)
Proteína Morfogenética Ósea 7/uso terapéutico , Elevación del Piso del Seno Maxilar/métodos , Implantes Absorbibles , Adulto , Atrofia , Densidad Ósea/fisiología , Regeneración Ósea/efectos de los fármacos , Sustitutos de Huesos/uso terapéutico , Trasplante Óseo/métodos , Colágeno , Implantes Dentales , Durapatita/uso terapéutico , Femenino , Estudios de Seguimiento , Humanos , Masculino , Maxilar/patología , Seno Maxilar/efectos de los fármacos , Seno Maxilar/patología , Membranas Artificiales , Persona de Mediana Edad , Minerales/uso terapéutico , Oseointegración/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Piezocirugía/métodos , Proyectos Piloto , Estudios Prospectivos , Tomografía Computarizada por Rayos X/métodos
19.
J Otolaryngol Head Neck Surg ; 41(4): 253-8, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22935176

RESUMEN

OBJECTIVE: The purpose of this study was to investigate the effects of hepatocyte growth factor (HGF) on healing of the sinonasal mucosa. METHODS: A 6 mm wound was created in the bilateral maxillary sinuses of 16 New Zealand White rabbits, and 8 mm diameter absorbable gelatin sponge with 25 µL HGF (case) and 25 µL saline (control) were randomly assigned to each side for wound treatment. On the third and seventh days after the procedure, the average decreased diameter was recorded. On the seventh day, the medial wall of the maxillary sinus was taken for histologic analysis (including scanning electron microscopy of two rabbits). The maximal thickness of fibrous tissue and no epithelium coverage of the wound were detected. In the second, third, and fourth weeks, another 3 rabbits were randomly selected for photographs under a scanning electron microscope. RESULTS: On the third and seventh days after injury, the average decreased diameters were 2.05 ± 0.56 mm and 1.56 ± 0.80 mm, 3.90 ± 0.76 mm, and 3.29 ± 0.70 mm on the case and control sides, respectively. On day 7 after injury, the maximal thickness of fibrous tissue was 324.8 ± 93.1 µm and 432.8 ± 106.3 µm, and the wound without epithelium coverage was 345.7 ± 114.6 µm and 508.6 ± 157.2 µm on case and control sides, respectively, and there were significant differences (p < .05). CONCLUSIONS: HGF can promote wound healing and ciliogenesis and inhibit fibrosis in the maxillary sinus mucosa, especially in the first 3 days. This finding suggests that HGF plays a potential role in reepithelialization and cilium hyperplasia.


Asunto(s)
Factor de Crecimiento de Hepatocito/administración & dosificación , Seno Maxilar/efectos de los fármacos , Mucosa Nasal/efectos de los fármacos , Heridas y Lesiones/tratamiento farmacológico , Administración Tópica , Animales , Modelos Animales de Enfermedad , Femenino , Esponja de Gelatina Absorbible , Masculino , Seno Maxilar/patología , Mucosa Nasal/patología , Conejos , Cicatrización de Heridas/efectos de los fármacos , Heridas y Lesiones/patología
20.
Eur Ann Otorhinolaryngol Head Neck Dis ; 129(5): 244-50, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22921302

RESUMEN

AIM: Intranasal aerosol administration of drugs is widely used by ENT specialists. Although clinical evidence is still lacking, intranasal nebulization appears to be an interesting therapeutic option for local drug delivery, targeting anatomic sites beyond the nasal valve. The sonic nebulizer NL11SN associates a 100Hertz (Hz) sound to the aerosolization to improve deposition in the nasal/paranasal sinuses. The aim of the present study was: to evaluate in vivo the influence of associating a 100Hz sound on sinus ventilation and nasal and pulmonary aerosol deposition in normal volunteers, and; to quantify in vitro aerosol deposition in the maxillary sinuses in a plastinated head model. MATERIAL AND METHODS: Scintigraphic analysis of (81m)Kr gas ventilation and of sonic aerosol ((99m)Tc-DTPA) deposition using the NL11SN was performed in vivo in seven healthy volunteers. In parallel, NL11SN gentamicin nebulization was performed, with or without associated 100Hz sound, in a plastinated human head model; the gross amount of gentamicin delivered to the paranasal sinuses was determined by fluorescence polarization immunoassay. RESULTS: Associating the 100Hz sound to (81m)Kr gas ensured paranasal sinus ventilation in healthy volunteers. (99m)Tc-DTPA particles nebulized with the NL11SN were deposited predominantly in the nasal cavities (2/3, vs 1/3 in the lungs). In vitro, the use of NL11SN in sonic mode increased gentamicin deposition threefold in the plastinated model sinuses (P<0.002); the resulting antibiotic deposit would be sufficient to induce a local therapeutic effect. CONCLUSION: The NL11SN nebulizer ensured preferential nasal cavity aerosol deposition and successfully targeted the maxillary sinuses.


Asunto(s)
Antibacterianos/administración & dosificación , Gentamicinas/administración & dosificación , Seno Maxilar/efectos de los fármacos , Cavidad Nasal/efectos de los fármacos , Nebulizadores y Vaporizadores , Sonicación , Adulto , Algoritmos , Voluntarios Sanos , Humanos , Masculino , Seno Maxilar/diagnóstico por imagen , Modelos Anatómicos , Cavidad Nasal/diagnóstico por imagen , Rociadores Nasales , Senos Paranasales/efectos de los fármacos , Cintigrafía , Radiofármacos , Sonicación/métodos , Pentetato de Tecnecio Tc 99m
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA